Prospective, Observational, Multicentre Study Evaluating HCV Patients Characteristics of Eligibility and Disease Management in Real Clinical Practice.
Phase of Trial: Phase IV
Latest Information Update: 21 Nov 2012
At a glance
- Drugs Peginterferon alfa-2a; Peginterferon alfa-2b; Ribavirin
- Indications Hepatitis C
- Focus Therapeutic Use
- Sponsors Merck & Co; Schering-Plough
- 08 Nov 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 22 Sep 2011 Planned end date changed from 1 Aug 2011 to 1 Oct 2011 as reported by ClinicalTrials.gov.
- 09 Dec 2010 Planned End Date changed from 1 Jun 2011 to 1 Aug 2011 as reported by ClinicalTrials.gov.